8 sources checked · 2 source groups included · 29m ago
Still Watching
Novel m RNA cancer vaccine helps reduce chances of melanoma patients' tumors returning
NBC News and WPVI / 6abc Philadelphia describe the same event in different terms.
1 Left7 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of October 23, 2026 at 7:31 PM, this is how Optics News reads the wording differences in this story.
What happenedA first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
The headline splitThe left frames it as "Personalized m RNA vaccine for melanoma cut risk of cancer’s return in late-stage trial". The center frames it as "STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early".
Match confidenceMedium confidence. 8 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
8 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
61/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftPersonalized m RNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
NBC News · Center-left · News report
CenterNovel m RNA cancer vaccine helps reduce chances of melanoma patients' tumors returning
KABC / ABC7 Los Angeles · Center · News report
Right / center-rightNo matching source in this bucket yet.
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized m RNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
Personalized m RNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Moderna and Merck’s personalized m RNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
